Seeff L B, Wright E C, Finkelstein J D, Greenlee H B, Hamilton J, Leevy C M, Tamburro C H, Vlahcevic Z, Zimmon D S, Zimmerman H J, Felsher B F, Garcia-Pont P, Dietz A A, Koff R S, Kiernan T, Schiff E R, Zemel R, Nath N
Lancet. 1975 Nov 15;2(7942):939-41. doi: 10.1016/s0140-6736(75)90357-8.
A randomised, double-blind, controlled trial has been undertaken to compare the efficacy of hepatitis B immune globulin (H.B.I.G.) with that of immune serum globulin (I.S.G.) for the prophylaxis of viral hepatitis. Participants in the trial were individuals exposed accidentally to material infectious for hepatitis (primarily viral B hepatitis). Preliminary evaluation of the first 302 of the 561 individuals entered into the study indicates that H.B.I.G. significantly reduced the frequencies of both clinical and subclinical hepatitis during the first 3--4 months after the injection. Less than 10% of H.B.I.G. recipients had detectable anti-HBs at the sixth month after the injection, suggesting that H.B.I.G. might need to be given every 3--4 months to continually exposed individuals. Further long-term evaluation is required in order to define more clearly those most likely to benefit from H.B.I.G.
已开展一项随机、双盲、对照试验，以比较乙肝免疫球蛋白（H.B.I.G.）和免疫血清球蛋白（I.S.G.）预防病毒性肝炎的疗效。该试验的参与者是意外接触到具有肝炎传染性物质（主要是乙肝病毒）的个体。对纳入该研究的561名个体中的前302名进行的初步评估表明，H.B.I.G.在注射后的头3至4个月内显著降低了临床和亚临床肝炎的发生率。注射后第六个月，接受H.B.I.G.治疗的个体中不到10%可检测到抗-HBs，这表明对于持续暴露的个体，可能需要每3至4个月注射一次H.B.I.G.。需要进一步进行长期评估，以便更清楚地确定最有可能从H.B.I.G.中获益的人群。
